Evidence map›Paper›PMID 23045284›Full record

ArticleOncogene2013

Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.

L Derbal-Wolfrom, E Pencreach, T Saandi, M Aprahamian, E Martin, R Greferath, E Tufa, P Choquet, J-M Lehn, C Nicolau and 2 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02528526 (A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02528526 phase1 / phase2unknown statusnot on this mapstarted 2014, after this paper: background citation

A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia

TypeinterventionalSponsorUniversity of ZurichRan2014 to 2016Enrolled69ConditionsPancreatic Neoplasms, Hepatocellular Cancer, Cholangiocarcinoma, Colorectal NeoplasmsArmsOXY111A
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

L Derbal-WolfromINSERM U682, Strasbourg, France.
E Pencreach
T Saandi
M Aprahamian
E Martin
R Greferath
E Tufa
P Choquet
J-M Lehn
C Nicolau
I Duluc
J-N Freund
Inserm · FRInstitut de Science et d'Ingénierie Supramoléculaires · FRCentre National de la Recherche Scientifique · FRTufts University · USUniversité de Strasbourg · FR

Funding

Worldwide Cancer Research 08-0199
6 · The paper itself

Abstract

Preventing tumor neovascularisation is one of the strategies recently developed to limit the dissemination of cancer cells and apparition of metastases. Although these approaches could improve the existing treatments, a number of unexpected negative effects have been reported, mainly linked to the hypoxic condition and the subsequent induction of the pro-oncogenic hypoxia inducible factor(s) resulting from cancer cells' oxygen starvation. Here, we checked in vivo on colon cancer cells an alternative approach. It is based on treatment with myo-inositol trispyrophosphate (ITPP), a molecule that leads to increased oxygenation of tumors. We provide evidence that ITPP increases the survival of mice in a model of carcinomatosis of human colon cancer cells implanted into the peritoneal cavity. ITPP also reduced the growth of subcutaneous colon cancer cells xenografted in nu/nu mice. In the subcutaneous tumors, ITPP stimulated the expression of the homeobox gene Cdx2 that is crucial for intestinal differentiation and that also has an anti-tumoral function. On this basis, human colon cancer cells were cultured in vitro in hypoxic conditions. Hypoxia was shown to decrease the level of Cdx2 protein, mRNA and the activity of the Cdx2 promoter. This decline was unrelated to the activation of HIF1α and HIF2α by hypoxia. However, it resulted from the activation of a phosphatidylinositol 3-kinases-like mitogen-activated protein kinase pathway, as assessed by the fact that LY294002 and U0126 restored high Cdx2 expression in hypoxia. Corroborating these results, U0126 recapitulated the increase of Cdx2 triggered by ITPP in subcutaneous colon tumor xenografts. The present study provides evidence that a chemical compound that increases oxygen pressure can antagonize the hypoxic setting and reduce the growth of human colon tumors implanted in nu/nu mice.

Indexed as

Oxygen ConsumptionAnimalsCDX2 Transcription FactorCell Line, TumorCell ProliferationColonic NeoplasmsDisease Models, AnimalGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansHypoxiaInositol PhosphatesMAP Kinase Signaling SystemMiceProto-Oncogene Proteins c-aktTumor BurdenCDX2 protein, humanCDX2 Transcription FactorHomeodomain ProteinsInositol Phosphatesinositol trispyrophosphateProto-Oncogene Proteins c-akt

Identifiers

PMID23045284
OpenAlexW2085678794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.